Recent Updates
Recently added Catalysts

epothilone b

Phase 2

Breast Neoplasms | Small molecule | Oncology |Novartis AG|Last Updated: Feb 8, 2017

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment46
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00035126EPO906 Therapy in Patients With Advanced Breast CancerPHASE2 COMPLETED 46 — — Jan 1, 2002Nov 1, 2003Feb 8, 20172 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Tumor response as assessed by radiologic techniques and/or physical examination based on Response Evaluation Criteria in Solid Tumors (RECIST)
Every 8 weeks
Secondary Endpoints
Time to progression
until disease progression, death or date of last follow-up
Overall survival
date of death or last date patient was known to be alive
Duration of overall response
every 8 weeks as clinically needed
Unlock Study Endpoints
Study Design & Arms
AllocationNON_RANDOMIZED
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
EPO906EXPERIMENTAL -
Interventions
NameTypeDescription
epothilone bDRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 85 Years
SexFEMALE
Healthy VolunteersNo
Study Sites2

Inclusion Criteria: The following patients may be eligible for this study: * Histologically or cytologically documented evidence of disease with at least one measurable lesion; * Life expectancy of greater than three (3) months; * Patients who have had only one prior therapy for metastatic disease...

Countries:United States
Unlock Eligibility Criteria